# BOND-3 (NCT02292758)

> Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02292758
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Academic and Community Cancer Research United
- Conditions: Colorectal Adenocarcinoma; RAS Wild Type; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
- Interventions: Bevacizumab; Cetuximab; Irinotecan; Laboratory Biomarker Analysis; Placebo
- Enrollment: 36
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: 6-month and 12-month Progression-free Survival (PFS) Rates

## Indexed commentary on BOND-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 11
- Podcasts: 4
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=bond-3-nct02292758

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02292758", "email": "<work email>"}; the inbox owner confirms by the emailed link.